A major shift is happening in the world of genetic data. Regeneron, a big name in biotechnology, is stepping in to buy 23andMe, a company known for its DNA testing kits. The price tag? A cool $256 million. This move comes as 23andMe faces bankruptcy, but Regeneron has plans to keep the company running smoothly. They want to honor the privacy promises made to 23andMe'...
A major change is happening in the world of genetic testing. Regeneron, a big name in pharmaceuticals, is set to buy 23andMe. The company is paying $256 million for this deal. This purchase happened after 23andMe went through a tough time and had to sell off its assets. 23andMe is known for its genetic testing kits. It has a huge database of personal and genetic inf...
The company 23andMe is in a tough spot. It is struggling financially and dealing with a major data breach. This has raised serious questions about the future of the genetic data of its 15 million customers. The firm, once a leader in DNA testing, is now facing an uncertain future. Its value has dropped drastically since it went public in 2021. The company has never m...
T-cell acute lymphoblastic leukemia, or T-ALL, is a tricky cancer where T-cells go wrong and start multiplying out of control. It is important to break down T-ALL into groups. This helps doctors figure out the best way to treat it. It's usually grouped into three categories: early T-cell precursor (ETP)-ALL, near-ETP-ALL, and non-ETP-ALL. But classifying T-ALL based...
Scientists often use genetic data to figure out how closely related different organisms are. One common way they do this is by using something called a Markov substitution model. This model helps them understand how changes, or substitutions, happen in molecular sequences over time. The general time reversible model, or GTR, is a popular choice for DNA data. It's eas...
You might think adding genetic information to clinical data can boost how well we predict health risks. But guess what? Tests show it can lead to different results. Scientists wrapped their heads around this by mixing clinical and genetic data from patient records. They wanted to figure out which decisions matter the most for the models' performance. It turns out th...
You've sent your saliva to 23andMe for genetic testing, but what happens if the company runs into trouble? Recently, 23andMe announced they're letting go of 40% of their staff. After their board resigned last year, the company's stock nosedived, raising doubts about its future. CEO Anne Wojcicki says she wants to take the company private, but customers are worried ab...